In AD, we observed a strong decrease in prevalence of tau positivity with older age, which has also been previously reported (with comparable effect sizes) using quantitative thresholds.36,37 Potential explanations could be that with older age, there may be additional development of copathologies or less resilience to tau, and therefore a lower tau-threshold may be needed to result in cognitive impairment. The gene discussed is MAPT; the disease is Alzheimer disease.